Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict lung cancer outcomes before surgery

NCT ID NCT05382052

Knowledge-focused Sponsor: Fundación GECP Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at 100 people with stage IIIA lung cancer who are getting treatment before surgery. Researchers want to see if a blood test that looks for tumor DNA (ctDNA) can predict how well patients do. If the tumor DNA disappears after treatment, it might mean a better chance of staying cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could show that a simple blood test (ctDNA) helps doctors predict which lung cancer patients will do well after pre-surgery treatment, guiding better care.
What could go wrong
This is an observational study, not a treatment trial. It only looks for patterns, so it won't directly change care. Results may not apply to all patients or be conclusive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Resectable stage IIIA non-small cell lung cancer patients that are going to receive neoadjuvant treatment in real world.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Previously untreated patients with histologically- or cytologically- documented NSCLC who present stage IIIA disease (according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) and also, potentially resectable locally advanced NSCLC patients' stage IIIB with T3N2 disease according to 8th edition can be included. * 2\. Tumor should be considered resectable before study entry by a multidisciplinary team * 3\. ECOG 0-1 * 4\. Age ≥ 18 years at time of study entry * 5\. Patients that are going to be treated with neoadjuvant treatment before surgery * 6\. Patient capable of proper therapeutic compliance and accessible for correct follow-up * 7\. Patients must have signed, dated and IRB/EC-approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care. Exclusion Criteria: * 1\. Patients who refuse to sign and date an IRB/IEC-approved written informed consent form. * 2\. No possibility of venipuncture * 3\. Any medical, mental, or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neoadjuvant treatment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neoadjuvant treatment Non-small cell lung cancer (stage III)

Contacts and locations

Locations

  • Complejo Hospitalario de Navarra

    Pamplona, Iruña, 31008, Spain

  • Hospital Clínico San Carlos

    Madrid, Madrid, 28040, Spain

  • Hospital Clínico Universitario de Valladolid

    Valladolid, Valladolid, 47003, Spain

  • Hospital Clínico de Valencia

    Valencia, Valencia, 46010, Spain

  • Hospital De Basurto

    Bilbao, Bilbao, 48013, Spain

  • Hospital General Universitario de Alicante

    Alicante, Alicante, 03010, Spain

  • Hospital Germans Trias I Pujol

    Badalona, Barcelona, 08916, Spain

  • Hospital Universitari Quiron Dexeus

    Barcelona, Barcelona, 08028, Spain

  • Hospital Universitari Son Llatzer

    Palma de Mallorca, Palma de Mallorca, 07198, Spain

  • Hospital Universitari Vall d' Hebron

    Barcelona, Barcelona, 08035, Spain

  • Hospital Universitario De A Coruna

    A Coruña, A Coruña, 15006, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Madrid, 28040, Spain

  • Hospital Universitario La Fe

    Valencia, Valencia, 46026, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, Lugo, 27003, Spain

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Madrid, 28222, Spain

  • Hospital Universitario Regional de Málaga

    Málaga, Málaga, 29010, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Córdoba, 14004, Spain

  • Hospital Universitario de Jaén

    Jaén, Jaén, 23007, Spain

  • Hospital Universitario la Paz

    Madrid, Madrid, 28046, Spain

  • ICO Girona, Hospital Josep Trueta

    Girona, Girona, 17007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.